News Daily News ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events Michael O'Riordan April 04, 2017
News Daily News Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER Michael O'Riordan June 14, 2016
News Daily News Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV Michael O'Riordan December 15, 2015
News Daily News Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee Michael O'Riordan December 15, 2015